Cancer Genetics, Inc. Announces Compelling Diagnostic Sensitivity (99%) And Accuracy (93%) For Its Patent-Protected Genomic Kidney Cancer Test
Published: Mar 05, 2014
RUTHERFORD, N.J. and SAN DIEGO, March 5, 2014 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq:CGIX) ("CGI") announced today the results of a collaborative study conducted with The Cleveland Clinic to validate CGI's kidney cancer microarray test. The CGI kidney cancer microarray facilitates the diagnosis, sub-typing, and outcome prediction of kidney cancer patients. This study demonstrated that the diagnostic sensitivity of the test is 93%, with 99% specificity. The clinical validation study was performed using samples from 188 kidney cancer patients treated at the Cleveland Clinic. Accurately diagnosing kidney cancer using pathology alone is challenging, and can delay time to first treatment if surgical resections are required.
Help employers find you! Check out all the jobs and post your resume.